Combination of KRAS gene silencing and PI3K inhibition for ovarian cancer treatment
The phosphoinositide 3-kinase (PI3K) and RAS signaling pathways are frequently co-activated and altered during oncogenesis. Owing to their regulatory cross-talk, the early attempts of targeting only one pathway have mostly ended up promoting the development of drug resistance. Here, we propose using small interfering RNA (siRNA) therapeutics to directly target the undruggable KRAS (siKRAS) in combination with the pan-PI3K inhibitor GDC-0941 (GDC) to simultaneously block both PI3K and RAS signaling, thereby exerting synergistic anti-tumor effects on ovarian cancers with PTEN deficiency and KRAS
Authors
Funding
Targeting the p110beta isoform of PI3 kinase in prostate cancerMolecular mechanisms and therapeutic targeting of PI3K-p110beta/PTEN signaling in breast cancer and cancer immunityMolecular mechanisms and therapeutic targeting of PI3K-p110beta/PTEN signaling in breast cancer and cancer immunityTargeting the p110beta isoform of PI3 kinase in prostate cancerKorea Institute of Science and Technology Grant 2E29370